|1.||Scarpa, Aldo: 9 articles (04/2009 - 06/2003)|
|2.||Donadelli, Massimo: 8 articles (04/2009 - 06/2003)|
|3.||Palmieri, Marta: 8 articles (04/2009 - 06/2003)|
|4.||Ma, Ding: 7 articles (02/2015 - 09/2005)|
|5.||Karagiannis, Tom C: 6 articles (08/2012 - 10/2010)|
|6.||Zhou, Jianfeng: 5 articles (01/2014 - 09/2005)|
|7.||Wu, Peng: 5 articles (01/2014 - 09/2005)|
|8.||Kook, Hyun: 5 articles (11/2011 - 09/2003)|
|9.||Righetti, Pier Giorgio: 5 articles (04/2009 - 06/2003)|
|10.||Cecconi, Daniela: 5 articles (04/2009 - 06/2003)|
12/01/2014 - "In this study, human cancer cells were treated with the HDACI trichostatin A (TSA). "
05/01/2011 - "In this study, we investigate the roles of trichostatin A (TSA), a typical HDAC inhibitor, on three non-cancer cell lines AML-12, MDCK and 3T3-L1, and four cancer cell lines Hep-3B, HeLa, A549 and MCF-7. "
01/01/2011 - "In the present study, we demonstrated that trichostatin A (TSA), a well-known HDAC inhibitor (HDACi), significantly induced ATX expression in SW480 and several other cancer cells with low or undetectable endogenous ATX expression. "
01/01/2007 - "The aim of this study was to evaluate the in vitro tumoricidal activity of the Apo2L/TRAIL + Trichostatin A in cultured thoracic cancer cells and to elucidate the molecular basis of the synergistic cytotoxicity of this combination. "
09/16/2005 - "For the first time, our study demonstrated that trichostatin A (TSA) briefly activated the proliferation of cervical cancer cell lines, HeLa and SiHa, within 12 h, but then inhibited cell growth after that time point. "
|2.||Lung Neoplasms (Lung Cancer)
10/01/2014 - "Then it was used to retrieve relevant small molecule drugs with Connectivity map and trichostatin A was predicted to be the top candidate drug for treatment of lung cancer. "
08/01/2010 - "Four lung cancer cell lines lacking TRbeta1 expression were treated with 5-aza-2-deoxy-cytidine and/or trichostatin-A, and the TRbeta1 expression was determined by RT-PCR. "
04/01/2010 - "To explore the effect of trichostatin A (TSA) on human lung cancer cell strains A549. "
04/01/2010 - "[Effects of trichostatin A on human lung cancer cell strains A549]."
12/31/2006 - "Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?"
08/01/2006 - "[Mechanism of apoptosis induced by trichostatin A in leukemia Molt-4 cells analyzed by microarray]."
09/01/1990 - "Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells."
08/01/2006 - "In this study, it was investigated whether trichostatin A (TSA), a specific histone deacetylase (HDAC) inhibitor and a new anticancer drug, could improve the anticancer activity of low concentrations of Cur in human leukemia cells (HL-60). "
02/01/2009 - "Active extracts of wild fruiting bodies of Antrodia camphorata (EEAC) induce leukemia HL 60 cells apoptosis partially through histone hypoacetylation and synergistically promote anticancer effect of trichostatin A."
08/01/2006 - "Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells."
04/01/2015 - "Protection against reperfusion lung injury via aborgating multiple signaling cascades by trichostatin A."
08/01/2014 - "Although studies have shown that chemical epigenetic modifiers can limit lung inflammation in experimental ALI models, studies to date have not examined efficacy of a combination of DNA methyl transferase inhibitor 5-Aza 2-deoxycytidine and histone deacetylase inhibitor trichostatin A (herein referred to as Aza+TSA) after endotoxemia-induced mouse lung injury. "
04/01/2006 - "Recently, we demonstrated the efficacy of the HDAC inhibitor Trichostatin A in ameliorating disease in the multiple sclerosis (MS) animal model, experimental autoimmune encephalomyelitis (EAE). "
07/01/2005 - "We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). "
|1.||Histone Deacetylase Inhibitors
|2.||vorinostat (suberoylanilide hydroxamic acid)
|3.||Histone Deacetylases (Histone Deacetylase)
|4.||Valproic Acid (Valproate, Semisodium)
|5.||Drug Therapy (Chemotherapy)